Equity Investments at a Premium in Biotech Licensings
Executive Summary
Alliance Watch focuses on alliances between established drug firms and public biotechs in which the larger partner bought equity at a premium to the company's average trading price for the 10 days prior to the deal's announcement.
You may also be interested in...
QUOTED. 4 March 2021. Meghan Scanlon.
Boston Scientific has agreed to pay $1.07bn to acquire Lumenis’ surgical laser business from Baring Private Equity Asia. See what Meghan Scanlon, president of Boston Scientific’s urology and pelvic health business, said about it here.
BrainStorm’s Phase III Data Do Not Support Clinical Benefit Of NurOwn In ALS, US FDA Says
Agency’s unusual public statement about an investigational product's development status may be aimed at countering bullish comments from the sponsor; FDA cites failure of pivotal trial on the primary and secondary endpoints and ‘modest excess in deaths’ with the cell therapy.
Setback For Athenex, Hanmi As CRL Requests New Trial
Hanmi partner Athenex has had a US complete response letter for its oral paclitaxel plus encequidar product for the treatment of metastatic breast cancer, amid concerns of safety risks associated with an increase in neutropenia-related sequelae. While the decision marks another setback for Hanmi in the US, Athenex is aiming to resolve the issues.
Need a specific report? 1000+ reports available
Buy Reports